Dealbreaker on MSN6d
First-in-Class Brain Cancer Drug Strikes a Chord With Jazz Pharma to the Tune of a $935M M&A DealJazz Pharmaceuticals’ acquisition of Chimerix brings a drug that could become the first approved therapy for a rare and ...
Jazz Pharmaceuticals is now committing $935 million ... These small molecules target certain G protein-coupled receptors and enzyme targets, altering their activity to lead to cancer cell death.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback